OKYO Pharma to Ring the Opening Bell at Nasdaq

Summary by AI BETAClose X

OKYO Pharma Limited announced that its executive team will ring the Nasdaq Opening Bell, celebrating advancements in its lead candidate, urcosimod, for neuropathic corneal pain, a condition lacking FDA-approved therapies. Recent positive Phase 2 results for urcosimod in neuropathic corneal pain demonstrated favorable nerve outcomes and pain reduction, with a larger multicenter trial planned for Q1 2026.

Disclaimer*

UK 100

Latest directors dealings